newsfilter
← Latest News
GlobeNewswire·

Prometheus Biosciences Provides Corporate Updates at the 40th Annual J.P. Morgan Healthcare Conference

- Fast Track Designation granted from U.S. Food and Drug Administration for PRA023 for the treatment of Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) - - New patent granted for PRA023 companion diagnostic (CDx) reinforces Prometheu